- Works count
- 1,012
- Citation count
- 51,443
- H-index
- 114
- i10-index
- 413
Research interests
Publications
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults
New England Journal of Medicine · 2023 · 10.1056/nejmoa2209604
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
New England Journal of Medicine · 2023 · 10.1056/nejmoa2303951
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
European Respiratory Journal · 2023 · https://doi.org/10.1183/13993003.00239-2023
Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
American Journal of Respiratory and Critical Care Medicine · 2023 · https://doi.org/10.1164/rccm.202301-0106pp
Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its Revision
American Journal of Respiratory and Critical Care Medicine · 2022 · 10.1164/rccm.202204-0671pp
From GOLD 0 to Pre-COPD
American Journal of Respiratory and Critical Care Medicine · 2020 · https://doi.org/10.1164/rccm.202008-3328pp
Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine · 2020 · https://doi.org/10.1164/rccm.202009-3533so
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines ‐ recommendations on the use of biologicals in severe asthma
Allergy · 2020 · https://doi.org/10.1111/all.14221
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
New England Journal of Medicine · 2019 · 10.1056/nejmoa1901963
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019
European Respiratory Journal · 2019 · https://doi.org/10.1183/13993003.00164-2019
Benralizumab for the Prevention of COPD Exacerbations
New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1905248
Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study
The Lancet Respiratory Medicine · 2019 · https://doi.org/10.1016/s2213-2600(19)30049-9
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial
The Lancet · 2018 · https://doi.org/10.1016/s0140-6736(18)30206-x
Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial
The Lancet · 2017 · 10.1016/s0140-6736(17)30188-5
Asthma
The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)33311-1
Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline
European Respiratory Journal · 2017 · https://doi.org/10.1183/13993003.00791-2016
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
The Lancet · 2016 · 10.1016/s0140-6736(16)31324-1
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
The Lancet · 2016 · 10.1016/s0140-6736(16)31354-x
Experimental Rhinovirus Infection as a Human Model of Chronic Obstructive Pulmonary Disease Exacerbation
American Journal of Respiratory and Critical Care Medicine · 2010 · 10.1164/rccm.201006-0833oc
T helper type 17-related cytokine expression is increased in the bronchial mucosa of stable chronic obstructive pulmonary disease patients
Clinical & Experimental Immunology · 2009 · https://doi.org/10.1111/j.1365-2249.2009.03965.x
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation
Nature Medicine · 2008 · 10.1038/nm1713
Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production
Proceedings of the National Academy of Sciences · 2008 · 10.1073/pnas.0804181105
Role of deficient type III interferon-λ production in asthma exacerbations
Nature Medicine · 2006 · 10.1038/nm1462
Infections and Airway Inflammation in Chronic Obstructive Pulmonary Disease Severe Exacerbations
American Journal of Respiratory and Critical Care Medicine · 2006 · 10.1164/rccm.200506-859oc
Differences in Airway Inflammation in Patients with Fixed Airflow Obstruction Due to Asthma or Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine · 2003 · 10.1164/rccm.200203-183oc
Increased Expression of the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in Peripheral Airways of Smokers with Chronic Obstructive Pulmonary Disease
American Journal of Respiratory and Critical Care Medicine · 2002 · 10.1164/rccm.2107139
The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics
Journal of Clinical Investigation · 2001 · 10.1172/jci12655
Rhinoviruses Infect the Lower Airways
The Journal of Infectious Diseases · 2000 · 10.1086/315513
Current projects
No projects listed.